Home » Emergent BioSolutions Inks $174 Million COVID-19 Manufacturing Contract With AstraZeneca
Emergent BioSolutions Inks $174 Million COVID-19 Manufacturing Contract With AstraZeneca
Maryland-based Emergent BioSolutions has secured a $174 million contract with AstraZeneca for large-scale manufacturing of drug substances for the UK company’s COVID-19 vaccine.
Emergent will provide contract development and manufacturing services at its Baltimore Bayview facility for the commercial supply of the vaccine.
The new agreement expands upon an $87 million contract the companies signed in June.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May